预约演示

更新于：2025-05-07

Edema, Cardiac

心源性水肿

更新于：2025-05-07

基本信息

别名

Cardiac Edema、Cardiac Edemas、Cardiac edema

+ [33]

简介

Abnormal fluid retention by the body due to impaired cardiac function or heart failure. It is usually characterized by increase in venous and capillary pressure, and swollen legs when standing. It is different from the generalized edema caused by renal dysfunction (NEPHROTIC SYNDROME).

关联

项与心源性水肿相关的药物

Tolvaptan Sodium Phosphate

托伐普坦磷酸钠

靶点

AVPR2

作用机制

AVPR2拮抗剂

在研机构

Fuji Yakuhin Co., Ltd. [+1]

原研机构

Otsuka Pharmaceutical Co., Ltd.

在研适应症

体液潴留 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

日本

首次获批日期2022-03-28

Etelcalcetide

盐酸依特卡肽

靶点

CaSR

作用机制

CaSR激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

欧盟 [+3]

首次获批日期2016-11-11

Tolvaptan

托伐普坦

靶点

AVPR2

作用机制

AVPR2拮抗剂

在研机构

Otsuka Pharmaceutical Co., Ltd. [+5]

原研机构

Otsuka Holdings Co., Ltd.

在研适应症

腹水 [+7]

非在研适应症

慢性低钠血症 [+12]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2009-05-19

项与心源性水肿相关的临床试验

NCT06949020

/ Not yet recruiting临床2期

Efficacy and Safety of JMKX003142 Injection in Heart Failure Patients With Volume Overload：A Phase II, Randomized, Double-blind, Placebo-controlled Study

To Evaluate the Safety, Efficacy, and Pharmacokinetic/Pharmacodynamics Characteristics of JMKX003142 injection Administered Randomly,Double-blind, Placebo-controlled Study in Chinese Cardiacl Edema Patients.

开始日期2025-06-01

申办/合作机构

江西济民可信集团有限公司

NCT06021860

/ Not yet recruiting临床4期

A Phase IV, Two-part, Open-label Study Assessing the Pharmacokinetics, Safety and Pharmacodynamics of Single and Multiple Doses of Spironolactone Oral Suspension in Pediatric Patients With Edema Due to Heart Failure or Cirrhosis

This is a 2-part, 2 periods per part, open-label study with spironolactone oral suspension in pediatric patients with edema due to HF or hepatic cirrhosis. Both study parts will evaluate the safety, PK and PD of multiple doses of spironolactone in patients aged from birth to ≤17 years of age.

开始日期2024-06-01

申办/合作机构

CMP Development LLC

JPRN-jRCT2071220069

/ Recruiting临床2期IIT

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Doseranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

开始日期2023-01-10

申办/合作机构-

100 项与心源性水肿相关的临床结果

登录后查看更多信息

100 项与心源性水肿相关的转化医学

登录后查看更多信息

0 项与心源性水肿相关的专利（医药）

登录后查看更多信息

692

项与心源性水肿相关的文献（医药）

2025-04-01·Ecotoxicology and Environmental Safety

Acute exposure of perchlorate on zebrafish larvae: Neurotoxicity during development

Article

作者: He, Qingnan ; Zhao, Mingyi ; Xue, Xiaoran ; Hu, Lin ; Yang, Yang ; Zhang, Zaiqiu

OBJECTIVEThis study aimed to assess the acute developmental toxicity of perchlorate exposure and identify its manifestation of neurotoxicity in zebrafish (Danio rerio) model.METHODSZebrafish larvae were exposed to sodium perchlorate at early developmental stages and the phenotypes of various developmental abnormalities were observed and recorded. Neurodevelopmental toxicity has been studied in particular in terms of central nervous system apoptosis, peripheral motor abnormalities, and abnormal autonomic motor behavior. Samples were processed for pathological, transcriptomic, and PCR analyses.RESULTSAcute exposure of zebrafish larvae to perchlorate resulted in developmental toxicity in a concentration-dependent manner. Heart rate abnormality (33 %), slow blood flow (37 %), abnormal size of liver (23 %), delayed yolk absorption (70 %), and abnormal body pigmentation (100 %) were observed in the 3.83 mg/mL group. Heart edema (10 %), heart rate abnormality (60 %), slow blood flow (67 %), abnormal size of liver (77 %), delayed yolk absorption (100 %), abnormalities in intestinal morphology (30 %), abnormal body pigmentation (100 %), and shorter body length (47 %) were observed in the 4.03 mg/mL group. Developmental neurotoxicity was characterized by brain apoptosis, damage to the central nervous system (P < 0.01) and peripheral motor neurons (P < 0.0001), and reduced autonomous motor distance (P < 0.01). Transcriptomic analysis revealed that c3a.1, c5, fga, fgb, and fgg were upregulated in the complement and coagulation cascades, and the mRNA levels of c3a.1, dusp1, slc2a6, purba, and klf9 were found upregulated in PCR.CONCLUSIONAcute perchlorate exposure on zebrafish larvae caused various developmental toxicity in a concentration-dependent manner, notably neurotoxicity. We believed the immunological and inflammatory responses were involved.

2025-04-01·BioMetals

Unravelling the developmental toxicity of heavy metals using zebrafish as a model: a narrative review

Review

作者: Firdous, Sayed Mohammed ; Manna, Sanjib

Developmental toxicity is the disruption of an organism's normal development which may occur in either the parent before conception or in the growing creature itself. Zebrafish (Danio rerio) are being employed as effective vertebrate models to evaluate the safety and toxicity of chemicals because they can breed multiple times in a year so we can observe the toxic effects in the next generation and their development mental stages can be observed and define clearly because their 1 cell stage to prime stage is transparent so we can observe the development of every organ also they have nearly about 80% genetic similarity with humans and shares the similar neuromodulatory structure along with multiple neurotransmitter. The recent research endeavours to examine the harmful outcome of various heavy metals such as cadmium, chromium, nickel, arsenic, lead, mercury, bismuth, iron, manganese, and thallium along with microplastics on zebrafish embryos when subjected to environmentally acceptable levels of every single metal in addition to co-exposure at various points in time. These heavy metals can alter the mRNA expression levels, increase the reactive oxygen species (ROS) generation, decrease antioxidant expression, damage neuronal function, alter neurotransmitter release, alter the expression of several apoptotic proteins, interfere with the different signalling pathways, decrease heat rates, increase malformations like - pericardial oedema, heart oedema, reduce in length tail bending abnormal formation in fins. Thereafter we concluded that due to its involvement in the food chain, it also causes severe effects on human beings.

2025-03-04·European Heart Journal - Case Reports

Midostaurin-associated perimyocarditis: a case report of severe cardiotoxicity of novel targeted treatments for acute myeloid leukaemia and review of the literature

Article

作者: Pennig, Lenhard ; Cornely, Oliver A ; Pfister, Roman ; Stemler, Jannik ; Kalkan, Alev

AbstractBackgroundMidostaurin is a multikinase inhibitor for the treatment of Fms-like tyrosine 3 (FLT3)-mutated acute myeloid leukaemia (AML). Cardiac adverse events like QTc-prolongation, pericardial effusion, and congestive heart failure have been described. Inflammatory diseases associated with midostaurin are rarely reported.Case summaryA 24-year-old man with newly diagnosed AML and FLT3-ITD mutation was treated with intensive remission-induction chemotherapy and midostaurin. After 5 days of midostaurin, the patient reported severe focal chest pain. Due to laboratory evidence of acute myocardial cell damage, coronary macroangiopathy and pulmonary artery embolism were ruled out via computed tomography. Cardiovascular magnetic resonance showed evidence for active perimyocarditis with myocardial oedema and late gadolinium of the basal, midventricular, and apical lateral wall of the left ventricle. Therapeutic drug monitoring did not reveal excessive midostaurin plasma levels, and hence, initially suspected drug interaction with posaconazole administered for antifungal prophylaxis was considered less likely to be causative. After discontinuing midostaurin, clinical signs of perimyocarditis improved. During continued high-dose cytarabine therapy, no further cardiac events occurred. It was concluded that perimyocarditis was an adverse effect of midostaurin since the inhibition of FTL3 may have led to a loss of cardiomyocyte protective capacity against oxidative stress-induced apoptosis, as previously described in vitro.DiscussionIn addition to the most frequently reported non-cardiac adverse effects of midostaurin, serious cardiotoxic complications appear to occur and may require discontinuation of therapy. This case highlights the importance of interdisciplinary work-up of a cardio-oncology pathway even in presumably low-risk patients and particularly in the context of rare cases of cardiotoxicity in novel cancer treatments.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。